Cargando…
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Aim: Sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy has been demonstrated to improve glycemic control and reduce body weight and fat mass in type 2 diabetes mellitus (T2DM). Here, our aim was to investigate the effects of SGLT2i dapagliflozin-treatment on body muscle mass and muscle fat...
Autores principales: | Sugiyama, Seigo, Jinnouchi, Hideaki, Kurinami, Noboru, Hieshima, Kunio, Yoshida, Akira, Jinnouchi, Katsunori, Nishimura, Hiroyuki, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Tomio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005223/ https://www.ncbi.nlm.nih.gov/pubmed/29225209 http://dx.doi.org/10.5551/jat.40873 |
Ejemplares similares
-
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018) -
Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018) -
Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2017) -
Body Muscle-to-Fat Ratio, Rather Than Fat-to-Muscle Ratio, Significantly Correlates With Measured Insulin Resistance in Patients With Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2021) -
Smoking Cessation Ameliorates Microalbuminuria With Reduction of Blood Pressure and Pulse Rate in Patients With Already Diagnosed Diabetes Mellitus
por: Hieshima, Kunio, et al.
Publicado: (2018)